 tax humira driver earn
messag continu believ humira despit good number remain
crux oper margin cash flow point immunolog
increasingli competit market fill non-tnf drug humira key indic
potenti competit horizon
abbvi humira inflammatori therapeut indic approv
use total sale virtual entir oper profit
busi fact tax rate estim principl driver
stock action today view tax rate base
newli announc tax reform lower today provid ep
guidanc rais guidanc midpoint
due lower tax rate
surpris abbv earn releas today sale mavyret hepat therapi
seen strong uptak intern accord manag
mavyret reach market leadership market launch
mavyret exit market share highli competit hcv market global
hcv sale nearli includ global sale mavyret approach
base launch manag expect hcv sale exceed
split vs ex-u
besid strong mavyret guidanc see previou note humira sale abbv
linchpin also stronger anticip us consensu us main question
realli boil humira sale origin obvious critic
oper margin cash flow overal market biolog immunolog grow
exampl comment crohn market grown certainli
must one element growth puzzl indic rheumatoid arthriti
crohn psoriasi compet product actual grow faster
importantli share humira remain stabl grow lose ground
market share data humira discuss call includ percentag
patient switch assum rather high support humira leadership
posit indic use howev wonder whether combin
market share data cosentyx novarti nv taltz johnson
johnson tremfya psoriasi caus dent humira psoriasi share
 exampl understand crohn stelera gain percentag
point share humira continu believ competit pressur
anoth key indic humira rheumatoid arthriti competit could
increas pend baricitinib approv remind initi launch olumi
germani compar humira histor launch trajectori see previou note
believ growth product may come expens humira furthermor
humira growth rate eu expect declin due biosimilar entri manag
expect ex-u humira sale peak today agre humira continu
gener suffici cash flow question growth rate
humira individu indic chang next year today
futur
updat estim base perform updat guidanc
manag commentari earn call base strong perform
humira imbruvica mavyret increas revenu estim
page analyst certif import disclosur
model humira revenu increas humira sale
yoy compani guidanc peak ou humira sale
addit updat oper margin expens estim base
guidanc provid manag call also brought
tax rate estim slight increas tax rate subsequ year
approach tax rate year adjust ep non-gaap
estim increas total oper revenu
valuat risk
valuat use forward price-to-earnings multipl valu share current trade
ep believ trade time forward earn
view fairli valu maintain neutral rate ep estim
revenu
risk earn assumpt predic continu growth largest
product humira manag high expect new product
hematolog cancer may met view growth hing
acceler demand entri market treat sever hematolog cancer
upsid risk may includ regulatori reimburs chang lead greater demand
sooner expect core revenue-gener product upsid risk includ
stronger expect uptak mavyret hep
page analyst certif import disclosur
million except per-shar figur
compani report guggenheim secur llc estim
page analyst certif import disclosur
